DABI-ADP-2: Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation.

Trial Profile

DABI-ADP-2: Impact of Dabigatran and Phenprocoumon on Clopidogrel Mediated ADP Induced Platelet Aggregation in Patients With Atrial Fibrillation.

Discontinued
Phase of Trial: Phase IV

Latest Information Update: 01 Jan 2015

At a glance

  • Drugs Dabigatran etexilate (Primary) ; Phenprocoumon
  • Indications Embolism; Stroke; Venous thromboembolism
  • Focus Therapeutic Use
  • Acronyms Dabi-ADP-2
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 01 Jul 2013 Planned End Date changed from 1 Mar 2013 to 1 May 2014 as reported by ClinicalTrials.gov.
    • 24 Apr 2012 Planned end date changed from 1 Mar 2012 to 1 Mar 2013 as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top